Having established the efficacy of anti CGRP monoclonal antibodies in terms of migraine frequency, pain intensity and disability, current research is focusing beyond these aspects of migraine, such as interictal disability, quality of life and migraine associated symptoms. Here, CALCA is linked to migraine disorder.